Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

Abstract:

:Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and allergic rhinitis. Interestingly, some patients responding to oxatomide were said to be unresponsive to previously administered antihistamines. The effect of oxatomide was little different from placebo in clinical trials of bronchial asthma in adults. While somewhat more encouraging results have been reported in children with bronchial asthma when higher than presently recommended dosages were employed, and in follicular conjunctivitis, atopic dermatitis and food allergy, reports to date are largely preliminary in nature and additional well-controlled studies are needed to clarify the efficacy of oxatomide in such conditions. The drug has been generally well tolerated, but shares some of the familiar H1-histamine receptor antagonist side effects. As with other similarly acting drugs, the 2 primary side effects with oxatomide are drowsiness and weight gain. Thus, on the basis of present evidence, a trial with oxatomide seems a potentially useful alternative in patients with conditions known or thought to be allergic in nature, in whom more established treatments were ineffective or poorly tolerated.

journal_name

Drugs

journal_title

Drugs

authors

Richards DM,Brogden RN,Heel RC,Speight TM,Avery GS

doi

10.2165/00003495-198427030-00003

subject

Has Abstract

pub_date

1984-03-01 00:00:00

pages

210-31

issue

3

eissn

0012-6667

issn

1179-1950

journal_volume

27

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.

    abstract::Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of < 1% in solid tumors. Detection of TRK fusions can be based on fluorescence in-si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01459-w

    authors: Rohrberg KS,Lassen U

    更新日期:2021-01-05 00:00:00

  • Hypopigmentary skin disorders: current treatment options and future directions.

    abstract::Alterations of skin and hair pigmentation are important features that have warranted treatment from ancient history on up to modern time. In some cultures, even today patients with vitiligo are regarded as social outcasts and are affected considerably both emotionally and physically. This article presents current opti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464010-00006

    authors: Hartmann A,Bröcker EB,Becker JC

    更新日期:2004-01-01 00:00:00

  • Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

    abstract::Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00013

    authors: Wiseman LR,Markham A

    更新日期:1996-10-01 00:00:00

  • Steroid-refractory severe ulcerative colitis: what are the available treatment options?

    abstract::Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868090-00001

    authors: Moss AC,Peppercorn MA

    更新日期:2008-01-01 00:00:00

  • Antiarrhythmic therapies for the prevention of sudden cardiac death.

    abstract::Despite remarkable advances in cardiovascular therapeutics, sudden cardiac death remains a significant problem. In this review, data from clinical trials and other studies on antiarrhythmic therapies have been evaluated in order to determine effective strategies for the prevention of sudden cardiac death in high risk ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754020-00003

    authors: McAlister FA,Teo KK

    更新日期:1997-08-01 00:00:00

  • Sacituzumab Govitecan: First Approval.

    abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01337-5

    authors: Syed YY

    更新日期:2020-07-01 00:00:00

  • Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function.

    abstract::Because of inappropriate signals from the volume-regulation system and a reduction in renal blood flow, the kidney is not able to prevent sodium and water retention in chronic congestive heart failure (CHF). A brief summary of normal renal function and renal involvement in CHF is given and a study of renal function in...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199000394-00004

    authors: Ljungman S,Laragh JH,Cody RJ

    更新日期:1990-01-01 00:00:00

  • Drug treatment of tropical parasitic infections: recent achievements and developments.

    abstract::Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00002

    authors: Stephenson I,Wiselka M

    更新日期:2000-11-01 00:00:00

  • Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.

    abstract::Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01443-4

    authors: Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

    更新日期:2020-11-28 00:00:00

  • Pharmacokinetics of various preparations of organic nitrates.

    abstract::The pharmacokinetics of different formulations of glyceryl trinitrate, isosorbide dinitrate, isosorbide 5-mononitrate and isosorbide 2-mononitrate are reviewed. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198700334-00004

    authors: Kampmann JP

    更新日期:1987-01-01 00:00:00

  • Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.

    abstract::Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action (both direct and indirect) thought to be involved in its anti-myeloma activity. Oral pomalidomide is available in several countries for use in combination with low-dose dexamethasone in adult...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0833-y

    authors: Hoy SM

    更新日期:2017-11-01 00:00:00

  • Management of patients with advanced non-small cell lung cancer: current and emerging options.

    abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11532200-000000000-00000

    authors: Triano LR,Deshpande H,Gettinger SN

    更新日期:2010-01-01 00:00:00

  • Inhibitory effects of nedocromil sodium on the in vitro induced migration and leukotriene formation of human granulocytes.

    abstract::Inflammatory cells, such as neutrophils and eosinophils, are thought to actively contribute to the pathogenesis of asthma since they infiltrate into the lung tissue and may be activated locally to release bronchoconstrictor mediators. In this study we provide evidence that nedocromil sodium is capable of effectively i...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198900371-00004

    authors: Bruijnzeel PL,Warringa RA,Kok PT,Hamelink ML,Kreukniet J

    更新日期:1989-01-01 00:00:00

  • Activity of quinolones against mycobacteria.

    abstract::The fluoroquinolones have been shown to be active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis complex and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best stud...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958002-00004

    authors: Jacobs MR

    更新日期:1999-01-01 00:00:00

  • Platelets, thrombosis and drugs.

    abstract::The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197509010-00003

    authors: Mustard JF,Packham MA

    更新日期:1975-01-01 00:00:00

  • Treating ocular hypertension to reduce glaucoma risk: when to treat?

    abstract::When to treat the patient who presents with ocular hypertension has been a question that has 'stumped' the ophthalmic community for decades. Population-based studies and intervention trials have provided the basis for understanding why we consider treating such patients. Although the EGPS (European Glaucoma Prevention...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666080-00001

    authors: Higginbotham EJ

    更新日期:2006-01-01 00:00:00

  • Inflammatory bowel disease management. Some thoughts on future drug developments.

    abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753020-00001

    authors: Rhodes J,Thomas G,Evans BK

    更新日期:1997-02-01 00:00:00

  • Epidemiology and therapy of Chlamydia trachomatis infections.

    abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198427050-00005

    authors: Bowie WR

    更新日期:1984-05-01 00:00:00

  • Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.

    abstract::Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empaglifl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0457-z

    authors: Kim ES,Deeks ED

    更新日期:2015-09-01 00:00:00

  • Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.

    abstract::Sitagliptin (Januvia, Glactiv(R), Tesavel(R)) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Oral sitagliptin as monotherapy or combination therapy was generally well tolerated and improved glycaemic control in well designed clinical trials in patients with type 2 diabet...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11203790-000000000-00000

    authors: Dhillon S

    更新日期:2010-03-05 00:00:00

  • Antihistamines: pharmacology and clinical use.

    abstract::Antihistamines are a diverse group of drugs which possess the ability to inhibit various histaminic actions. By and large, they bear a certain structural resemblance to histamine, and act principally to prevent histamine-receptor interaction through competition with histamine for histamine receptors. Consequently, the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197612040-00002

    authors: Pearlman DS

    更新日期:1976-01-01 00:00:00

  • Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.

    abstract::Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11635960-000000000-00000

    authors: Ryan J,Ancelin ML

    更新日期:2012-09-10 00:00:00

  • Aspirin for Prevention of Preeclampsia.

    abstract::Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to deter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0823-0

    authors: Atallah A,Lecarpentier E,Goffinet F,Doret-Dion M,Gaucherand P,Tsatsaris V

    更新日期:2017-11-01 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).

    abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345040-00002

    authors: Sandström E,Oberg B

    更新日期:1993-04-01 00:00:00

  • Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

    abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01145-6

    authors: Raterman HG,Bultink IEM,Lems WF

    更新日期:2019-07-01 00:00:00

  • Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

    abstract::Rabeprazole is an inhibitor of the gastric proton pump. It causes dose-dependent inhibition of acid secretion and has a more rapid onset of action than omeprazole. Duodenal ulcers healed faster after treatment with rabeprazole 20 or 40 mg/day than placebo or ranitidine 150 mg 4 times daily and at a generally similar r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958040-00014

    authors: Langtry HD,Markham A

    更新日期:1999-10-01 00:00:00

  • Combination antiretroviral therapy. Back to the future.

    abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500491-00008

    authors: Lange J

    更新日期:1995-01-01 00:00:00

  • Vaccination strategies in lymphomas and leukaemias: recent progress.

    abstract::The successful identification of a range of leukaemia-specific and lymphoma-specific antigens in recent years has stimulated efforts to develop therapeutic vaccination strategies. A number of clinical trials have established the safety and immunogenicity of vaccination against tumour antigens, although there are limit...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11593270-000000000-00000

    authors: Rezvani K,de Lavallade H

    更新日期:2011-09-10 00:00:00

  • Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.

    abstract::Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluores...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0409-7

    authors: Keating GM

    更新日期:2015-05-01 00:00:00